4th Quarter - Report

ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$650,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 21, 2014 $650,000 Replaced
4th Quarter - Amendment Mar 26, 2014 $650,000 Replaced
4th Quarter - Amendment May 2, 2014 $560,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Intellectual property and market access issues

LobbyistCovered position, as disclosed
BRADLEY ALLEN ROSSIN —

Contacted: U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA); SENATE; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Reform of tax code and possible timing of any such reform bill (no bill number yet)

LobbyistCovered position, as disclosed
BRADLEY ALLEN ROSSIN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR); Commerce, Dept of (DOC)

Copyright/Patent/Trademark CPT

H.R. 3309, S 1720, S 1013, S 1612 - patent litigation reform

LobbyistCovered position, as disclosed
CARRIE HARNEY —
THERESA JOLIVETTE —
BELA SASTRY —

Contacted: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA)

Bills named: H.R. 3309 (113th)

Health Issues HCR

Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program H.R. 3204 and related legislative proposals - Drug safety and supply chain protections H.R. 3742 - Legislative proposals regarding the development of antibiotics H.R. 2725, S. 1413 - FDA user feesFederal revenues, entitlement reform, and deficit reduction regarding ongoing fiscal talks and sequestration General discussions regarding patient adherence to prescribed medications regimens

LobbyistCovered position, as disclosed
CARRIE HARNEY —
THERESA JOLIVETTE —
JACQUELINE POMFRET KIRBY —
BELA SASTRY —
ANDREA WILKINSON New SenBreaux, MerchMar&FishComm, CongMcCrery

Contacted: Health Resources & Services Administration (HRSA); Commerce, Dept of (DOC); SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2725 (113th), S. 1413 (113th), H.R. 3204 (113th), H.R. 3742 (113th)

Medicare/Medicaid MMM

H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to adherence programs H.R. 1588, S. 740 - issues related to pharmaceutical rebates in Medicare Part D

LobbyistCovered position, as disclosed
THERESA JOLIVETTE —
JACQUELINE POMFRET KIRBY —
BELA SASTRY —
ANDREA WILKINSON New SenBreaux, MerchMar&FishComm, CongMcCrery

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; Commerce, Dept of (DOC); Health Resources & Services Administration (HRSA)

Bills named: H.R. 3590 (113th), S. 740 (113th), H.R. 1588 (113th)

Consumer Issues/Safety/Products CSP

H.R. 3204 and related legislative proposals - Drug safety and supply chain protections

LobbyistCovered position, as disclosed
CARRIE HARNEY —
THERESA JOLIVETTE —
BELA SASTRY —

Contacted: U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Health Resources & Services Administration (HRSA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3204 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.